May 18, 2022

Blog @ Munaf Sheikh

Latest news from tech-feeds around the world.

Futurism: New COVID-19 test is fast, accurate, and low-cost


A new test for COVID-19 combines the speed of over-the-counter antigen tests with the accuracy of PCR tests processed in medical labs and hospitals.

The Harmony COVID-19 test is a diagnostic test that, like PCR tests for COVID-19, detects genetic material from the SARS-CoV-2 virus. But while conventional PCR tests can take several hours, the Harmony kit can provide results in less than 20 minutes for some samples and with similar accuracy.

“We designed the test to be low-cost and simple enough that it could be used anywhere,” says Barry Lutz, an associate professor of bioengineering at the University of Washington, investigator with the Brotman Baty Institute for Precision Medicine, and senior author of the paper in Science Advances. “We hope that the low cost will make high-performance testing more accessible locally and around the world.”

The researchers developed Harmony to be simple and easy-to-use, employing ready-to-use reagents. The test uses a “PCR-like” method to detect the presence of the SARS-CoV-2 RNA genome in a nasal swab sample with the aid of a small, low-cost detector, which Lutz’s group also designed. A smartphone is used to operate the detector and read the results. The detector can handle up to four samples at a time and would fit into a standard car’s glove compartment.

The accuracy of COVID-19 tests has been a pressing matter throughout the pandemic. Many at-home antigen kits for COVID-19, which detect pieces of the proteins the virus creates instead of its genetic material, are 80-85% accurate, though accuracy may drop with the Omicron variant, which harbors a relatively high number of mutations not found in other strains.

PCR tests are generally 95% accurate or better—a key FDA benchmark—but require expensive equipment and a long wait for results.

“We plan to make our test accessible and affordable throughout the world.”

Initial results reported in the paper show that the Harmony kit is 97% accurate for nasal swabs. The Harmony kit detects three different regions of the virus’ genome. If a new variant has many mutations in one region, the new test can still detect the other two. It can, for example, detect the Omicron variant, which has dozens of mutations in the region of the genome that encodes the so-called spike protein.

Though tests based on PCR—or polymerase chain reaction—are highly accurate, a key limitation is that PCR tests require dozens of cycles of heating and cooling to detect genetic material in a sample. The new test, which Lutz and his team developed, sidesteps this issue by relying on a PCR-like method known as RT-LAMP, which doesn’t have the same stringent temperature-cycling requirements.

“This test operates at a constant temperature, so it eliminates the time to heat and cool and gives results in about 30 minutes,” Lutz says.

Initially, Lutz and his team hope the kits could be made available first for use in clinics, as well as other settings with medical oversight, such as workplaces and schools. Later, they would like to adapt the test for home use.

“For a long time, the options have been either a PCR test that is expensive and typically takes a day or more to get a result, or a rapid antigen test that gives fast results and is low cost, but typically has lower accuracy than a lab PCR test,” says Lutz. “From the first day, we designed our test to be manufacturable at low cost and high volume, while delivering fast results with PCR-like performance.

“We plan to make our test accessible and affordable throughout the world,” says Lutz.

Lutz and two colleagues spun out a new company, Anavasi Diagnostics, which last year was supported by $300,000 from WE-REACH and later received $14.9 million in grants from the National Institutes of Health to develop the Harmony prototype kit into a product and scale up manufacturing to help address the ongoing shortage of COVID-19 diagnostic tests. The NIH funding will support high-volume manufacturing at a new Anavasi facility near Seattle.

The Seattle Flu Study and the National Institutes of Health funded the work.

Source: University of Washington



Source link